Drug profile · INN
ixazomib citrate
NINLARO
ixazomib citrate (NINLARO) is a 26s proteosome inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
Drug details — ixazomib citrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 2
- Programs
- 25
- Data quality
- 0.89
Quick answer
ixazomib citrate (NINLARO) is a 26s proteosome inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
26S proteosome inhibitor
Primary target: 26S proteasome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is ixazomib citrate?
ixazomib citrate (NINLARO) is a 26s proteosome inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ixazomib citrate?
NINLARO is a marketed brand name for ixazomib citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ixazomib citrate?
ixazomib citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.